Clinical trials: Small-Cell Lung Cancer
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Small Cell Lung Cancer
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment…
- Trial name
- NCT06064500
- Testing
- Tarlatamab
- Where
- 23 sites in United States, Brazil and 2 more
- Sponsor
- Amgen
Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
The objective of this study is to evaluate the bioequivalence of a tablet formulation versus a capsule formulation of ASP8273 following a single dose under fasted condition in subjects with non-small cell lung cancer (NSCLC)…
- Trial name
- NCT03082300
- Testing
- naquotinib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Carcinoma, Non-Small-Cell Lung, Surgery--Complications
Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery
Delirium is a common complication in elderly patients after surgery. And its occurrence is associated with worse outcomes. The causes of delirium are multifactorial but may include pain, stress response and inflammation.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Surgery--Complications, Dexamethasone, Flubiprofen Axetil
- Trial name
- NCT03200600
- Testing
- Dexamethasone, Normal saline, Flurbiprofen axetil
- Where
- 2 sites in China
- Volunteers
- 126 people
- Sponsor
- Peking University First Hospital
Small Cell Lung Cancer
Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)
This trial aims to evaluate the efficacy and safety between radiotherapy alone and concurrent chemo-radiotherapy after 3-4 cycles of chemotherapy in LS-SCLC.
- Trial name
- SCLC (NCT01745445)
- Testing
- concurrent chemo-radiotherapy arm
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer, Endostatin
Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC
To evaluate the efficacy and safety of recombinant human endostatin /PD-1 mab combined with first-line chemotherapy in the treatment of driver gene negative advanced non-small cell lung cancer.
- Trial name
- NCT05448781
- Testing
- Endostatin
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling pathway inhibitor RO4929097 (RO4929097) and erlotinib hydrochloride when given together in treating patients with non-small cell lung…
- Trial name
- NCT01193881
- Testing
- Erlotinib Hydrochloride, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
This is a phase I/II, open-label and multi-center study of SY-3505, a third-generation ALK TKI, in patients with advanced ALK-positive non-small cell lung cancer (ALK-positive NSCLC).
- Trial name
- NCT05257512
- Testing
- SY-3505
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
Small Cell Lung Cancer
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
- Trial name
- NCT02815592
- Testing
- BMS-986012, Cisplatin, Etoposide
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Non Small Cell Lung Cancer
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients.
- Trial name
- COPE (NCT04258137)
- Testing
- Liquid biopsy
- Where
- 6 sites in France
- Volunteers
- 332 people
- Sponsor
- Institut Bergonié
Myelosuppression
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on…
- Trial name
- NCT06490081
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer
- Trial name
- NCT03023319
- Testing
- Bosutinib, Pemetrexed
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nagla Abdel Karim
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Disitamab Vedotin combined therapy locally advanced or metastatic NSCLC Patients with HER2 Alterations.
- Conditions
- Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin
- Trial name
- NCT05847764
- Testing
- RC48+Tislelizumab+carboplatin, RC48+Furmonertinib, 1L, RC48+Furmonertinib, 2L+
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Sun Yat-sen University
Lung Cancer (NSCLC)
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
This is a single arm, open-label exploratory study conducted in resectable stage II-IIIA NSCLC without EGFR/ALK mutations, aiming to investigate feasibility, safety and efficacy of Sugemalimab in perioperative contexts.
- Trial name
- NCT06987734
- Testing
- Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer (NSCLC)
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can…
- Trial name
- NCT05553834
- Testing
- Alirocumab and Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Previous Treated Metastatic Non-small Cell Lung Cancer
Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer
- Trial name
- NCT01783834
- Testing
- Gefitinib, Pemetrexed
- Where
- South Korea
- Volunteers
- 95 people
- Sponsor
- Gachon University Gil Medical Center
Lung Cancer, Lung
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of…
- Conditions
- Lung Cancer, Lung, Lung Cancer (NSCLC), Metabolomics
- Trial name
- NCT06843707
- Testing
- Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.
- Where
- China
- Volunteers
- 2,500 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non Small Cell Lung Cancer
Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer
The purpose of the study is to evaluate the response rate of patients with non small lung cancer to gemcitabine in combination with radiotherapy. The tolerability and safety of this combination will also be evaluated.
- Trial name
- NCT00192036
- Testing
- gemcitabine, cisplatin, radiation
- Where
- 8 sites in Belgium
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, Depression
Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression
This is a phase II, placebo-controlled, randomized, double-blinded clinical trial. Study objective is to assess the efficacy and safety of mirtazapine in advanced NSCLC patients with malignant tumor related depression.
- Trial name
- NCT02650544
- Testing
- Mirtazapine
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
A phase II, multicenter, randomized, double-blind, placebo-controlled study was carried out. Patients were randomly assigned to the treatment (PC + pegylated endostatin) or the control group (PC+ placebo).
- Trial name
- NCT01527864
- Testing
- pegylated endostatin and Paclitaxel-Carboplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.